During the course of our synthetic and screening endeavors, we have identified a range of approaches to both diverse and highly specialized (focused) compound selections. These libraries have been extensively validated in our in-house biological assays as well as in the laboratories of over 200 external partners including Pharma, Biotech, Academia and Screening Centers in the U.S., Europe and Japan. Currently, we offer a shelf-available set of over 1,6 M individual solid screening compounds. A custom selection that suits your specific screening needs could be dispatched in any custom format to you within 2-3 weeks.
Our computational, structural biology, synthetic and medicinal chemistry team follow current trends in modern structure-based drug discovery to add novel diverse and targeted compounds. The latter selections are aimed at tackling multiple targets, protein domains, pathways, cellular processes, etc. Representative examples of these biased libraries include modulators of numerous protein-protein interactions, stem cell differentiation, apoptosis, proteasome cascade including diverse ligases, autophagy, epigenetics machinery, cell cycle including quiescent cancer cells, motor proteins, mitochondrial homeostasis and cell energetic, viral targets, bacterial genome, protein folding machinery including scaffolding proteins and chaperones and many others. We have also assembled screening sets for agrochemical, cosmetics and food industries reflective of the Generally Recognized As Safe (GRAS) concepts.
Our general approach to these sets include analysis of the available chemical and biological information, identification of key pathway nodules/targets, computational and ‘wet biology’ assessment of target druggability and potential binding domains. The resulting information is analyzed by our synthetic team in order to design scaffolds that are likely to interact with the designated targets yielding focused compound libraries. For the current list please visit our focused libraries list link. This selection is updated on a quarterly basis reflective of novel insight into molecular, cell biology, availability of novel ligands or overall trends in disease areas.
Our libraries observe modern definitions of lead-like properties. Our multidisciplinary team has put forth specialized libraries focused on chemical diversity-, soluble diversity-, blood-brain permeability, rigid topology (spiro-heterocycles and macrolide analogues), Fsp3 character, medium- and large-size rings (macrocycles) and other criteria.
Chemical arrays as small as 20 and as large as 500 members can be custom-made or picked up from the existing stock reflective of the structure-based assessment of a target or pathway. Notably, all compounds are chosen to exhibit a range of drug like and lead like properties. Generally, our team requests ca. 2 weeks to generate and propose set of libraries (10-25+) addressing your biological interest(s).
Needless to say, all libraries are regularly updated at the rate of 100K new compounds per year with our novel, IP-defined compounds resulting from the internal development. We are always pleased to consider and adopt your custom protocols in order to make focused compound set(s) that suit your specific needs (see our Template Model™). Our highly diverse molecules are produced using ‘traditional’ synthetic approaches with yields of up to 100-150 mg per compound and average purity greater than 92% as determined by both NMR and LCMS analyses. Complimentary to our proprietary chemotypes, we also offer a selection of custom building blocks.
In addition to producing libraries, we could be your partner of choice for screening. For the list of our in vitro, ex vivo and in vivo assay capabilities, please visit this Biology Services link.
If you have an existing therapeutic target but no chemical starting point, we can be your partner to find such a lead.
Chemical arrays between 100-500 members can be prepared or picked up from existing stock around pharmaceutically accepted templates, designed to have a range of drug like and lead like properties. We need 1-2 weeks to generate and propose set of libraries (10-25+) towards customer target or select it immediately from existing stock of 1.6 M compounds.
ChemDiv, Inc. introduces the concept of Targeted Diversity which is intended for the design of high quality library of drug-like compounds that have been focused against various biological targets. More than 300 distinct druggable targets selected for universe Targeted Diversity Library (uTDL) design.
Discovery collection includes various focused libraries. The selection process for these sets involves identifying active ligands/inhibitors as prototypes existing in the patent and research literature or databases and performing bioisosteric replacement strategies.
Fragment Library – Recently fragment-based drug discovery (FBDD) has emerged as a more promising and focused approach which is resulting in the quality, rather than the quantity, of hits and leads. Non-peptide Peptidomimetic Library – Arg, Pro, Glu, Asp; beta-, gamma-turns; dipeptide- and tripeptide mimic including RGD, AVPI and PDZ motifs, beta sheet, SH2 mimics.